Tigenix

Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases.

placeLeuven, Flemish Region, Belgium calendar_todayFounded 2000 groups89 employees language tigenix.com

Registered entities

Innovation

14 patent families (7 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 425 times.

YearFilings
20126
20134
20145
20152
20163
20171
20181
20191
20201
20231

Investor mix

20 investors on record; lead investors include ING Bank; 1 has since exited.

Investor typeCountShare
Venture capital945%
Private equity15%
Bank & private debt15%
Other / undisclosed945%
Coming soon